Compare TRNO & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRNO | GRFS |
|---|---|---|
| Founded | 2009 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.8B |
| IPO Year | 2009 | N/A |
| Metric | TRNO | GRFS |
|---|---|---|
| Price | $62.65 | $8.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 2 |
| Target Price | ★ $67.83 | $10.15 |
| AVG Volume (30 Days) | 585.0K | ★ 646.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.29% | 1.74% |
| EPS Growth | ★ 103.65 | N/A |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $476,383,000.00 | N/A |
| Revenue This Year | $7.62 | $5.33 |
| Revenue Next Year | $8.75 | $6.50 |
| P/E Ratio | ★ $16.15 | $18.67 |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $53.00 | $6.19 |
| 52 Week High | $67.70 | $11.14 |
| Indicator | TRNO | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 30.37 |
| Support Level | $59.00 | $7.64 |
| Resistance Level | $62.75 | $9.11 |
| Average True Range (ATR) | 1.20 | 0.30 |
| MACD | -0.53 | -0.11 |
| Stochastic Oscillator | 32.23 | 4.38 |
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.